(Q35193683)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

The systemic treatment of advanced and metastatic bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Nicholas D James

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

489-497

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

High-risk metastatic urothelial cancer: chances for cure?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Current understanding of the biology of advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

Organ preservation strategies in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901168-9

7 January 2021

10.1016/S1470-2045(03)01168-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901963%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference